Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Jader the Paperwork Reduction Act of 1995, no persons are required to respond

ubstitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/823,447			
Filing Date	04/13/2004			
First Named Inventor	Scott Baron			
Art Unit				
Examiner Name				
Attomory Dookst Number	DCOOFFTA			

Francisco.	C'4-	Danis at March and	U. S. PATENT D		Description of the same of the same
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	<u> </u>	US-			
	 	US-			
		US-			
		US-	-		
		US-		,	
		US-			`
		US-			
:		US-			
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages			
		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶		
	wo	00/20450						
	ļ							
				l				

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



									_
Please	type a	plus	sign ((+)	inside	this	box	\rightarrow	+

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known				
Application Number	10/823,447			
Filing Date	April 13, 2004			
First Named Inventor	Scott Baron			
Group Art Unit				
Examiner Name				
Attorney Docket Number	PC20557A			

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
		McLean MJ et al "Gabapentin as add-on therapy in refratory partial epilepsy" Neurol. 1993;43:2292-2298	
		Field et al "Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity" Br. J. Pharmacol. 2001; 132:1-4	9
		Mauri MC et al "Gabapentin and the prophylaxis of bipolar disorders in patients intolerant to lithium" Clin. Drug invest. 2001;21(3):169-174	
		Takasaki I. et al "Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection" Pharmacol. Exp. Ther. 2001;296(2):270-275	
		Bauer CA and Brozoski TJ "Assessing tinnitus and prospective tinnitus therapeutics using a psychophysical animal model" JARO 2001;2/1:54-64	
		Mathew NT et al "Efficacy of gabapentin in migraine prophylaxis" Headache 2001;41:119-128	
		Loprinzi CL et al "Pilot evaluation of gabapentin for treating hot flashes" Mayo Clin. Proc. 2002;77(11):1159-1163	
		Brown JP and Gee NS "Cloning and deletion mutagenesis of the alpha2delta calcium channel subunit from porcine cerebral cortex" J. Biol. Chem. 1998;273:25458-25465	
·		Stefani A et al "The efects of gabapenitn on different ligand-and voltage-gated currents in isolated cortical neurons" Epilepsy Research 2001;43(3)239-238	
		Ng GY et al "Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action" Mol. Pharmacol. 2001;59(1):144-152	
.2		Wang M et al "Structural requirement of the calcium-channel subunit alpha2delta for gabapentin binding" Bioche. J. 1999;342:313-320	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box 🛶	△	
ridase type a pius sign (+) inside tilis box 🛶	ፆ │ ┼	

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Comple	te if Known
				Application Number	10/823,447
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	April 13, 2004
				First Named Inventor	Scott Baron
				Group Art Unit	
	(use as many	sheet	s as necessary)	Examiner Name	
Sheet	3	of	4	Attorney Docket Number	PC20557A

Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Brown JP et al "Isolation of the [3H]gabapentin-binding protein/alha2delag Ca2+ channel subunit from procine brain: development of a radioligand binding assay for alpha2delta subunits using [3H]leucine" Biochem. 1998;255(2):236-243 Anantharaman V and Aravind L "Cache-a signaling domain common to animal Ca2+-channel subunits class of prokaryotic chemotaxis receptors" Trends Biochem. Sci. 2000;25(11):535-537 Bork P and Rohde K "More von Willebrand factor typ A domains? Sequence similarities with malaria thrombospondin-related anonymous protein, dihydropyridine-sensitive calcium channel and inter-alpha-trypsin inhibitor" Biochem. J. 1991;279(3):908-910 Wattler, S. et al "Construction of gene targeting vectors from lambdaKOS genomic libraries" Bio Techniques 1999;26:1150-1160	n Anal.	T2
procine brain: development of a radioligand binding assay for alpha2delta subunits using [3H]leucine" Biochem. 1998;255(2):236-243 Anantharaman V and Aravind L "Cache-a signaling domain common to animal Ca2+-channel subunits class of prokaryotic chemotaxis receptors" Trends Biochem. Sci. 2000;25(11):535-537 Bork P and Rohde K "More von Willebrand factor typ A domains? Sequence similarities with malaria thrombospondin-related anonymous protein, dihydropyridine-sensitive calcium channel and inter-alpha-trypsin inhibitor" Biochem. J. 1991;279(3):908-910 Wattler, S. et al "Construction of gene targeting vectors from lambdaKOS genomic libraries" Bio	Anal.	
class of prokaryotic chemotaxis receptors" Trends Biochem. Sci. 2000;25(11):535-537 Bork P and Rohde K "More von Willebrand factor typ A domains? Sequence similarities with malaria thrombospondin-related anonymous protein, dihydropyridine-sensitive calcium channel and inter-alpha-trypsin inhibitor" Biochem. J. 1991;279(3):908-910 Wattler, S. et al "Construction of gene targeting vectors from lambdaKOS genomic libraries" Bio	and a	
thrombospondin-related anonymous protein, dihydropyridine-sensitive calcium channel and inter-alpha-trypsin inhibitor" Biochem. J. 1991;279(3):908-910 Wattler, S. et al "Construction of gene targeting vectors from lambdaKOS genomic libraries" Bio		
ACCESSION: M76559; DEFINITION: Human neuronal DHP-sensitive, voltage-dependent, calcium calpha-2b subunit mRNA, complete cds.	hannel	
ACCESSION: U73483; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta sub alpha2a isoform mRNA, complete cds.	ınit,	
ACCESSION: U73484; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta sub alpha2b isoform mRNA, complete cds.	unit,	
ACCESSION: U73485; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta subunit, alpha2c isoform mRNA, complete cds.		
ACCESSION: U73486; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta sub alpha2d isoform mRNA, complete cds.	unit,	
ACCESSION: U73487; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta subunit, alpha2e isoform mRNA, complete cds.		
ACCESSION: M86621; DEFINITION: Rat dihydropyridine-sesitive L-type calcium channe alpha-2 subunit (CCHL2A) gene, complete cds.	:1	
<u> </u>	alpha2/delta subunit, alpha2e isoform mRNA, complete cds. ACCESSION: M86621; DEFINITION: Rat dihydropyridine-sesitive L-type calcium channe	alpha2/delta subunit, alpha2e isoform mRNA, complete cds. ACCESSION: M86621; DEFINITION: Rat dihydropyridine-sesitive L-type calcium channel

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Please	type	a plus	sign (+	inside	this box	->	+

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
•				Application Number	10/823,447	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	April 13, 2004	
				First Named Inventor	Scott Baron	
•			. 2.07	Group Art Unit		
(use as many sheets as necessary)				Examiner Name		
Sheet	4	of	4	Attorney Docket Number	PC20557A	

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.	T²			
		ACCESSION: AF077665; DEFINITION: Sus scrofa voltage-dependent calcium channel alpha-2 delta subunit precursor, mRNA, complete cds.				
÷.						
Examine Signatur		Date Considered				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313



¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.